Plus Therapeutics is pleased to announce the presentation of three positive clinical data updates at the World Federation of Neuro-Oncology Societies (WFNOS) / Society for Neuro-Oncology (SNO) 2025 Annual Meeting. These new findings advance the Company’s growing body of evidence supporting its radiotherapeutic platform and highlight meaningful progress across both the ReSPECT-LM and ReSPECT-GBM clinical trials.
The updates reinforce the therapeutic potential of REYOBIQ™, Plus Therapeutics’ targeted radiopharmaceutical designed for intraventricular delivery to treat complex central nervous system (CNS) cancers.
Read the full press release: https://lnkd.in/g3ExQXnD
Key Clinical Highlights Presented at WFNOS / SNO 2025
1. ReSPECT-LM Trial: No Dose-Limiting Toxicity Observed in Multi-Dose Cohort 1
New data from Cohort 1 of the multi-dose ReSPECT-Leptomeningeal Metastases (LM) clinical trial demonstrated:
-
No dose-limiting toxicities associated with REYOBIQ administration
-
Continued evidence supporting the feasibility of repeated intraventricular dosing
-
Strong tolerability, reinforcing the potential of targeted radiotherapeutics in LM management
This milestone is particularly meaningful given the urgent unmet needs for patients with LM, a condition known for rapid progression and limited treatment options.
2. ReSPECT-GBM Trial Shows Encouraging Safety & Efficacy Signals
The ReSPECT-Glioblastoma (GBM) trial evaluating REYOBIQ as a novel therapeutic for recurrent GBM reported:
-
Promising safety results in treated patients
-
Early efficacy signals consistent with ongoing therapeutic benefit
-
Clear support for continued Phase 2 enrollment and clinical investigation
These data add to the growing evidence base suggesting that REYOBIQ’s targeted radiation profile may offer meaningful advantages in recurrent GBM, where survival outcomes remain poor with standard therapies.
3. MRI + SPECT Imaging Biomarkers Enable Precision Patient Assessment
Investigators also presented new findings showing that:
-
MRI combined with SPECT imaging biomarkers provides a precise way to evaluate survival response in recurrent GBM patients treated with REYOBIQ
-
This integrated imaging approach offers clinicians a more accurate tool for monitoring therapeutic activity and guiding personalized treatment planning
This capability further strengthens the clinical application of REYOBIQ and supports more informed decision-making throughout the treatment journey.
Advancing the Future of CNS Radiotherapeutics
Collectively, these three presentations highlight Plus Therapeutics’ progress toward establishing REYOBIQ as a next-generation radiotherapeutic for CNS cancers. With compelling data emerging from both LM and GBM programs, Plus Therapeutics continues to advance its mission of improving outcomes for patients facing some of the most difficult-to-treat malignancies.
Explore the ReSPECT Clinical Trials
To learn more about ongoing clinical programs for LM and GBM, including eligibility and study details, visit:
https://lnkd.in/gwiWkPy9
Recent Comments